Gilead Sciences, Inc. (NASDAQ:GILD) will be releasing its earnings data on Tuesday, February 2nd. Persons interested in listening to the company’s earnings conference call can do so using this link.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 83.00 on Friday. Gilead Sciences, Inc. has a 1-year low of $82.33 and a 1-year high of $123.37. The stock has a market cap of $119.62 billion and a PE ratio of 7.62. The stock’s 50 day moving average is $96.84 and its 200-day moving average is $105.15.

In other Gilead Sciences news, CEO John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, January 4th. The shares were sold at an average price of $97.68, for a total transaction of $9,768,000.00. Following the transaction, the chief executive officer now directly owns 3,948,066 shares of the company’s stock, valued at $385,647,086.88. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, January 4th. The shares were sold at an average price of $99.20, for a total transaction of $198,400.00. Following the transaction, the executive vice president now directly owns 48,783 shares in the company, valued at $4,839,273.60. The disclosure for this sale can be found here.

A number of analysts recently weighed in on the stock. Oppenheimer reiterated an “outperform” rating and set a $124.00 price target on shares of Gilead Sciences in a research note on Saturday. Needham & Company LLC reiterated a “buy” rating and set a $125.00 price target on shares of Gilead Sciences in a research note on Wednesday. Barclays reiterated an “overweight” rating on shares of Gilead Sciences in a research note on Tuesday, January 26th. Wells Fargo reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, January 22nd. Finally, Credit Suisse reiterated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, January 20th. Eight analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $125.10.

Gilead Sciences, Inc. (NASDAQ:GILD), is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. Its Liver Diseases products include Harvoni, Sovaldi, Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

12 Month Chart for NASDAQ:GILD

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.